Holly A Swartz1, Ellen Frank, Yu Cheng. 1. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. swartzha@upmc.edu
Abstract
OBJECTIVES: The differential roles of psychotherapy and pharmacotherapy in the management of bipolar (BP) II depression are unknown. As a first step toward exploring this issue, we conducted a pilot study to evaluate the feasibility and acceptability of comparing a BP-specific psychotherapy [Interpersonal and Social Rhythm Therapy (IPSRT)] to quetiapine as treatments for BP-II depression. METHODS:Unmedicated individuals (n = 25) meeting DSM-IV criteria for BP-II disorder, currently depressed, were randomly assigned to weekly sessions of IPSRT (n = 14) or quetiapine (n = 11), flexibly dosed from 25-300 mg. Participants were assessed with weekly measures of mood and followed for 12 weeks. Treatment preference was queried prior to randomization. RESULTS: Using mixed effects models, both groups showed significant declines in the 25-item Hamilton Rating Scale for Depression [F(1,21) = 44, p < 0.0001] and Young Mania Rating Scale [F(1,21) = 20, p = 0.0002] scores over time but no group-by-time interactions. Dropout rates were 21% (n = 3) and 27% (n = 3) in the IPSRT and quetiapine groups, respectively. Overall response rates (defined as ≥ 50% reduction in depression scores without an increase in mania scores) were 29% (n = 4) in the IPSRT group and 27% (n = 3) in the quetiapine group. Measures of treatment satisfaction were high in both groups. Treatment preference was not associated with outcomes. CONCLUSIONS: Outcomes in participants with BP-II depression assigned toIPSRT monotherapy or quetiapine did not differ over 12 weeks in this small study. Follow-up trials should examine characteristics that predict differential response to psychotherapy and pharmacotherapy.
RCT Entities:
OBJECTIVES: The differential roles of psychotherapy and pharmacotherapy in the management of bipolar (BP) II depression are unknown. As a first step toward exploring this issue, we conducted a pilot study to evaluate the feasibility and acceptability of comparing a BP-specific psychotherapy [Interpersonal and Social Rhythm Therapy (IPSRT)] to quetiapine as treatments for BP-II depression. METHODS: Unmedicated individuals (n = 25) meeting DSM-IV criteria for BP-II disorder, currently depressed, were randomly assigned to weekly sessions of IPSRT (n = 14) or quetiapine (n = 11), flexibly dosed from 25-300 mg. Participants were assessed with weekly measures of mood and followed for 12 weeks. Treatment preference was queried prior to randomization. RESULTS: Using mixed effects models, both groups showed significant declines in the 25-item Hamilton Rating Scale for Depression [F(1,21) = 44, p < 0.0001] and Young Mania Rating Scale [F(1,21) = 20, p = 0.0002] scores over time but no group-by-time interactions. Dropout rates were 21% (n = 3) and 27% (n = 3) in the IPSRT and quetiapine groups, respectively. Overall response rates (defined as ≥ 50% reduction in depression scores without an increase in mania scores) were 29% (n = 4) in the IPSRT group and 27% (n = 3) in the quetiapine group. Measures of treatment satisfaction were high in both groups. Treatment preference was not associated with outcomes. CONCLUSIONS: Outcomes in participants with BP-II depression assigned to IPSRT monotherapy or quetiapine did not differ over 12 weeks in this small study. Follow-up trials should examine characteristics that predict differential response to psychotherapy and pharmacotherapy.
Authors: E Frank; M K Shear; P Rucci; J M Cyranowski; J Endicott; A Fagiolini; V J Grochocinski; P Houck; D J Kupfer; J D Maser; G B Cassano Journal: Am J Psychiatry Date: 2000-07 Impact factor: 18.112
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; William Coryell; Jean Endicott; Jack D Maser; David A Solomon; Andrew C Leon; Martin B Keller Journal: Arch Gen Psychiatry Date: 2003-03
Authors: Kathleen R Merikangas; Robert Jin; Jian-Ping He; Ronald C Kessler; Sing Lee; Nancy A Sampson; Maria Carmen Viana; Laura Helena Andrade; Chiyi Hu; Elie G Karam; Maria Ladea; Maria Elena Medina-Mora; Yutaka Ono; Jose Posada-Villa; Rajesh Sagar; J Elisabeth Wells; Zahari Zarkov Journal: Arch Gen Psychiatry Date: 2011-03
Authors: Allan H Young; Susan L McElroy; Michael Bauer; Nabil Philips; William Chang; Bengt Olausson; Björn Paulsson; Martin Brecher Journal: J Clin Psychiatry Date: 2010-01-26 Impact factor: 4.384
Authors: Holly A Swartz; Paola Rucci; Michael E Thase; Meredith Wallace; Elisa Carretta; Karen L Celedonia; Ellen Frank Journal: J Clin Psychiatry Date: 2018 Mar/Apr Impact factor: 4.384
Authors: Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller Journal: Int J Neuropsychopharmacol Date: 2017-02-01 Impact factor: 5.176